ZINC- zinc chloride injection, solution
Hospira, Inc.
--------

ZINC
1 mg/mL
Zinc Chloride Injection, USP

FOR I.V. USE ONLY AFTER DILUTION
Plastic Vial
Rx Only

DESCRIPTION
Zinc 1 mg/mL (Zinc Chloride Injection, USP) is a sterile, nonpyrogenic solution intended for use as an
additive to intravenous solutions for total parenteral nutrition (TPN). Each mL of solution contains 2.09
mg zinc chloride and 9 mg sodium chloride. The solution contains no bacteriostat, antimicrobial agent
or added buffer. The pH is 2.0 (1.5 to 2.5); product may contain hydrochloric acid and sodium
hydroxide for pH adjustment. The osmolarity is 0.354 mOsmoL/mL (calc.).

Zinc Chloride, USP is chemically designated ZnCl$_2$, a white crystalline compound freely soluble in
water.

Sodium Chloride, USP is chemically designated NaCl, a white crystalline compound freely soluble in
water.

The semi-rigid vial is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene
and propylene. The safety of the plastic has been confirmed by tests in animals according to USP
biological standards for plastic containers. The small amount of water vapor that can pass through the
plastic container wall will not significantly alter the drug concentration.

CLINICAL PHARMACOLOGY
Zinc is an essential nutritional requirement and serves as a cofactor for more than 70 different enzymes
including carbonic anhydrase, alkaline phosphatase, lactic dehydrogenase, and both RNA and DNA
polymerase. Zinc facilitates wound healing, helps maintain normal growth rates, normal skin hydration,
and the senses of taste and smell.

Zinc resides in muscle, bone, skin, kidney, liver, pancreas, retina, prostate and particularly in the red and
white blood cells. Zinc binds to plasma albumin, α$_2$-macroglobulin, and some plasma amino acids
including histidine, cysteine, threonine, glycine, and asparagine. Ingested zinc is excreted mainly in the
stool (approximately 90%), and to a lesser extent in the urine and in perspiration.

Providing zinc helps prevent development of deficiency symptoms such as: Parakeratosis, hypogeusia,
anorexia, dysosmia, geophagia, hypogonadism, growth retardation and hepatosplenomegaly.

The initial manifestations of hypozincemia in TPN are diarrhea, apathy and depression. At plasma levels
below 20 mcg zinc/100 mL dermatitis followed by alopecia has been reported for TPN patients.
Normal zinc plasma levels are 100 ± 12 mcg/100 mL.

INDICATIONS AND USAGE
Zinc 1 mg/mL (Zinc Chloride Injection, USP) is indicated for use as a supplement to intravenous
solutions given for TPN. Administration helps to maintain zinc serum levels and to prevent depletion of
endogenous stores, and subsequent deficiency symptoms.

CONTRAINDICATIONS
None known.

WARNINGS
Direct intramuscular or intravenous injection of Zinc 1 mg/mL (Zinc Chloride Injection, USP) is contraindicated as the acidic pH of the solution (2) may cause considerable tissue irritation.

Severe kidney disease may make it necessary to reduce or omit chromium and zinc doses because these elements are primarily eliminated in the urine.

WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

PRECAUTIONS

General
Do not use unless the solution is clear and the seal is intact.

Zinc 1 mg/mL (Zinc Chloride Injection, USP) should only be used in conjunction with a pharmacy directed admixture program using aseptic technique in a laminar flow environment; it should be used promptly and in a single operation without any repeated penetrations. Solution contains no preservatives; discard unused portion immediately after admixture procedure is completed.

Zinc should not be given undiluted by direct injection into a peripheral vein because of the likelihood of infusion phlebitis and the potential for increased excretory loss of zinc from a bolus injection. Administration of zinc in the absence of copper may cause a decrease in serum copper levels.

Laboratory Tests
Periodic determinations of serum copper as well as zinc are suggested as a guideline for subsequent zinc administration.

Carcinogenesis, Mutagenesis, and Impairment of Fertility
Long-term animal studies to evaluate the carcinogenic potential of Zinc 1 mg/mL (Zinc Chloride Injection, USP) have not been performed, nor have studies been done to assess mutagenesis or impairment of fertility.

Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Zinc 1 mg/mL (Zinc Chloride Injection, USP) is administered to a nursing woman.

Pediatric Use
See DOSAGE and ADMINISTRATION section.
Pregnancy
Animal reproduction studies have not been conducted with zinc chloride. It is also not known whether zinc chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Zinc chloride should be given to a pregnant woman only if clearly needed.

Geriatric Use
An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

ADVERSE REACTIONS
None known.

DRUG ABUSE AND DEPENDENCE
None known.

OVERDOSAGE
Single intravenous doses of 1 to 2 mg zinc/kg body weight have been given to adult leukemic patients without toxic manifestations. However, acute toxicity was reported in an adult when 10 mg zinc was infused over a period of one hour on each of four consecutive days. Profuse sweating, decreased level of consciousness, blurred vision, tachycardia (140/min), and marked hypothermia (94.2° F) on the fourth day were accompanied by a serum zinc concentration of 207 mcg/dl. Symptoms abated within three hours.

Hyperamylasemia may be a sign of impending zinc overdosage; patients receiving an inadvertent overdose (25 mg zinc/liter of TPN solution, equivalent to 50 to 70 mg zinc/day) developed hyperamylasemia (557 to 1850 Klein units; normal: 130 to 310).

Death resulted from an overdosage in which 1683 mg zinc was delivered intravenously over the course of 60 hours to a 72 year old patient.

Symptoms of zinc toxicity included hypotension (80/40 mm Hg), pulmonary edema, diarrhea, vomiting, jaundice, and oliguria, with a serum zinc level of 4184 mcg/dl.

Calcium supplements may confer a protective effect against zinc toxicity.

DOSAGE AND ADMINISTRATION
Zinc 1 mg/mL (Zinc Chloride Injection, USP) contains 1 mg zinc/mL and is administered intravenously only after dilution. The additive should be diluted prior to administration in a volume of fluid not less than 100 mL. For the metabolically stable adult receiving TPN, the suggested intravenous dosage is 2.5 to 4 mg zinc/day (2.5 to 4 mL/day). An additional 2 mg zinc/day (2 mL/day) is suggested for acute catabolic states. For the stable adult with fluid loss from the small bowel, an additional 12.2 mg zinc/liter of small bowel fluid lost (12.2 mL/liter of small bowel fluid lost), or an additional 17.1 mg zinc/kg of stool or ileostomy output (17.1 mL/kg of stool or ileostomy output) is recommended. Frequent monitoring of zinc blood levels is suggested for patients receiving more than the usual maintenance dosage level of zinc.

For full term infants and children up to 5 years of age, 100 mcg zinc/kg/day (0.1 mL/kg/day) is recommended. For premature infants (birth weight less than 1500 g) up to 3 kg in body weight, 300 mcg...
zinc/kg/day (0.3 mL/kg/day) is suggested.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (See PRECAUTIONS.).

HOW SUPPLIED

Zinc 1 mg/mL (Zinc Chloride Injection, USP) is supplied in 10 mL Plastic Vials.

<table>
<thead>
<tr>
<th>Unit of Sale</th>
<th>Concentration</th>
<th>Each</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDC 0409-4090-01</td>
<td>10 mg/10 mL</td>
<td>NDC 0409-4090-11</td>
</tr>
<tr>
<td>25 in a carton</td>
<td>(1 mg/mL)</td>
<td>10 mg vial</td>
</tr>
</tbody>
</table>

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

Distributed by Hospira, Inc., Lake Forest, IL 60045 USA
LAB-1069-1.0
Revised: 9/2017

PRINCIPAL DISPLAY PANEL - 10 mL Vial Label

10 mL Vial
ZINC
Rx only
10 mg/10 mL (1 mg/mL)
Zinc Chloride Inj., USP

FOR INTRAVENOUS USE ONLY AFTER DILUTION.
Distributed by Hospira, Inc., Lake Forest, IL 60045 USA

PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton

10 mL Vial
NDC 0409-4090-01
Contains 25 of NDC 0409-4090-11

ZINC
Rx only

10 mg/10 mL (1 mg/mL)

CAUTION: FOR INTRAVENOUS USE ONLY AFTER DILUTION.

Zinc Chloride Injection, USP

Hospira
# ZINC
zinc chloride injection, solution

## Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
<th>NDC:0409-4090</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>INTRAVENOUS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZINC CHLORIDE</td>
<td>ZINC CATION</td>
<td>1 mg in 1 mL</td>
</tr>
</tbody>
</table>

## Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM CHLORIDE</td>
<td>9 mg in 1 mL</td>
</tr>
<tr>
<td>HYDROCHLORIC ACID</td>
<td></td>
</tr>
<tr>
<td>SODIUM HYDROXIDE</td>
<td></td>
</tr>
</tbody>
</table>

## Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0409-4090-01</td>
<td>25 in 1 CARTON</td>
<td>09/30/1990</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>NDC:0409-4090-11</td>
<td>10 mL in 1 VIAL, PLASTIC; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA018959</td>
<td>09/30/1990</td>
<td></td>
</tr>
</tbody>
</table>

## Labeler - Hospira, Inc. (141588017)

## Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospira, Inc.</td>
<td>093132819</td>
<td>ANALYSIS(0409-4090), LABEL(0409-4090), MANUFACTURE(0409-4090), PACK(0409-4090)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospira, Inc.</td>
<td></td>
<td>827731089</td>
<td>ANALYSIS(0409-4090)</td>
</tr>
</tbody>
</table>

Revised: 11/2019

Hospira, Inc.